{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:34:30Z","timestamp":1787067270051,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12072-022-10365-0","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T07:03:01Z","timestamp":1654498981000},"page":"1161-1169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain"],"prefix":"10.1007","volume":"16","author":[{"given":"Jos\u00e9-Manuel","family":"Ramos-Rincon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Pinargote-Celorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"de Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Ramos-Belinch\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Trevi\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4624-5199","authenticated-orcid":false,"given":"Vicente","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"10365_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","volume":"45","author":"J Perez","year":"2006","unstructured":"Perez J, Armstrong G, Farrington L, Hutin Y, Bell B. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529\u2013538","journal-title":"J Hepatol"},{"key":"10365_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/23744235.2020.1766104","volume":"52","author":"O M\u00e5rdh","year":"2020","unstructured":"M\u00e5rdh O, Quinten C, Amato-Gauci A, Duffell E. Mortality from liver diseases attributable to hepatitis B and C in the EU\/EEA\u2014descriptive analysis and estimation of 2015 baseline. Infect Dis (Lond). 2020;52:625\u2013637","journal-title":"Infect Dis (Lond)"},{"key":"10365_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"W Seto","year":"2018","unstructured":"Seto W, Lo Y, Pawlotsky JM, Yuen M. Chronic hepatitis B virus infection. Lancet. 2018;392:2313\u20132324","journal-title":"Lancet"},{"key":"10365_CR4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","volume":"319","author":"L Tang","year":"2018","unstructured":"Tang L, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319:1802\u20131813","journal-title":"JAMA"},{"key":"10365_CR5","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1056\/NEJMcp041507","volume":"351","author":"G Poland","year":"2004","unstructured":"Poland G, Jacobson R. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med. 2004;351:2832\u20132838","journal-title":"N Engl J Med"},{"key":"10365_CR6","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"N Terrault","year":"2018","unstructured":"Terrault N, Lok A, McMahon B, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 chronic hepatitis B guidance. Hepatology. 2018;67:1560\u20131599","journal-title":"Hepatology"},{"key":"10365_CR7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","volume":"394","author":"C Spearman","year":"2019","unstructured":"Spearman C, Dusheiko G, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451\u20131466","journal-title":"Lancet"},{"key":"10365_CR8","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMra1810477","volume":"380","author":"D Thomas","year":"2019","unstructured":"Thomas D. Global elimination of chronic hepatitis. N Engl J Med. 2019;380:2041\u20132050","journal-title":"N Engl J Med"},{"key":"10365_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2468-1253(21)00218-1","volume":"6","author":"U Samarasekera","year":"2021","unstructured":"Samarasekera U. Urgent action needed to eliminate viral hepatitis by 2030. Lancet Gastroenterol Hepatol. 2021;6:611","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10365_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/QAD.0000000000001424","volume":"31","author":"V Soriano","year":"2017","unstructured":"Soriano V, Sherman K, Barreiro P. Hepatitis delta and HIV infection. AIDS. 2017;31:875\u2013884","journal-title":"AIDS"},{"key":"10365_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","volume":"7","author":"H Wedemeyer","year":"2010","unstructured":"Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31\u201340","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10365_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/nrgastro.2016.126","volume":"13","author":"F Lempp","year":"2016","unstructured":"Lempp F, Ni Y, Urban S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol. 2016;13:580\u2013589","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10365_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","volume":"73","author":"A Stockdale","year":"2020","unstructured":"Stockdale A, Kreuels B, Henrion M, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73:523\u2013532","journal-title":"J Hepatol"},{"key":"10365_CR14","first-page":"203","volume":"22","author":"M Toy","year":"2020","unstructured":"Toy M, Ahishali E, Yurdaydin C. Hepatitis delta virus epidemiology in the industrialized world. AIDS Rev. 2020;22:203\u2013212","journal-title":"AIDS Rev"},{"issue":"2","key":"10365_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jhep.2021.10.012","volume":"76","author":"A Loglio","year":"2022","unstructured":"Loglio A, Ferenci P, Uceda-Renteria S, et al. Safety and effectiveness of up to 3 years\u2019 bulevirtide monotherapy in patients with HDV-related cirrhosis. J Hepatol. 2022;76(2):464\u20139 (In press)","journal-title":"J Hepatol"},{"key":"10365_CR16","volume-title":"Combating hepatitis B and C to reach elimination by 2030","author":"WHO","year":"2016","unstructured":"WHO. Combating hepatitis B and C to reach elimination by 2030. Geneva: WHO; 2016"},{"key":"10365_CR17","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad. Real decreto 69\/2015, de 6 febrero, por el que se regula el Registro de Actividad Sanitaria Especializada. Bolet\u00edn del Estado 2015, 35, 1078\u20131080. Available online: http:\/\/www.boe.es\/eli\/es\/rd\/2015\/02\/06\/69\/con (Accessed on 15 Dec 2021)"},{"key":"10365_CR18","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/QAD.0000000000002508","volume":"34","author":"JM Ramos","year":"2020","unstructured":"Ramos JM, de Mendoza C, Aguilera A, et al. Hospital admissions in individuals with HTLV-1 infection in Spain. AIDS. 2020;34:1019\u20131027","journal-title":"AIDS"},{"key":"10365_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-021-01334-2","volume":"20","author":"A L\u00f3pez de Andr\u00e9s","year":"2021","unstructured":"L\u00f3pez de Andr\u00e9s A, Jim\u00e9nez-Garc\u00eda R, Hern\u00e1ndez-Barrera V, et al. Sex-related disparities in the incidence and outcomes of hemorrhagic stroke among type 2 diabetes patients: a propensity score matching analysis using the Spanish National Hospital Discharge Database for the period 2016\u201318. Cardiovasc Diabetol. 2021;20:138","journal-title":"Cardiovasc Diabetol"},{"key":"10365_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/QAD.0000000000003105","volume":"36","author":"JM Ramos-Rinc\u00f3n","year":"2022","unstructured":"Ramos-Rinc\u00f3n JM, Menchi-Elanzi M, Pinargote-Celorio H, et al. Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades. AIDS. 2022;36:249\u2013256","journal-title":"AIDS"},{"key":"10365_CR21","unstructured":"Ministerio de Sanidad y Consumo. Metodolog\u00eda de la hospitalizaci\u00f3n en el Sistema Nacional de salud. Available online: http:\/\/www.mscbs.gob.es\/estadEstudios\/estadisticas\/docs\/metod_modelo_cmbd_pub.pdf (accessed 15 Dec 2021)"},{"key":"10365_CR22","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/hep.31173","volume":"72","author":"J Paik","year":"2020","unstructured":"Paik J, Golabi P, Younossi Y, Mishra A, Younossi Z. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72:1605\u20131616","journal-title":"Hepatology"},{"key":"10365_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jhep.2018.05.011","volume":"69","author":"L Pimpin","year":"2018","unstructured":"Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718\u2013735","journal-title":"J Hepatol"},{"key":"10365_CR24","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1097\/MEG.0000000000001163","volume":"30","author":"A Aguilera","year":"2018","unstructured":"Aguilera A, Trastoy R, Rodriguez-Calvino J, Manso T, de Mendoza C, Soriano V. Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain. Eur J Gastroenterol Hepatol. 2018;30:1060\u20131062","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10365_CR25","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.15499","volume":"50","author":"K Liu","year":"2019","unstructured":"Liu K, Choi J, Le A, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther. 2019;50:1037\u20131048","journal-title":"Aliment Pharmacol Ther"},{"key":"10365_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025110","volume":"100","author":"A Nozaki","year":"2021","unstructured":"Nozaki A, Chuma M, Hara K, et al. Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: a prospective observational study. Medicine (Baltimore). 2021;100: e25110","journal-title":"Medicine (Baltimore)"},{"key":"10365_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-022-00776-3","author":"JM Ramos-Rincon","year":"2022","unstructured":"Ramos-Rincon JM, Pinargote H, de Mendoza C, et al. Hepatitis C hospitalizations in Spain and impact of new curative antiviral strategies. J Viral Hepat. 2022. https:\/\/doi.org\/10.1007\/s11908-022-00776-3","journal-title":"J Viral Hepat"},{"key":"10365_CR28","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2217\/fmb-2021-0177","volume":"16","author":"V Soriano","year":"2021","unstructured":"Soriano V, Mendoza C, Barreiro P, Trevi\u00f1o A, Corral O. Envisioning a hepatitis delta cure with new antivirals. Future Microbiol. 2021;16:927\u2013930","journal-title":"Future Microbiol"},{"key":"10365_CR29","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/jvh.13572","volume":"28","author":"J Na","year":"2021","unstructured":"Na J, Sinn D, Lee J, et al. Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. J Viral Hepat. 2021;28:1392\u20131399","journal-title":"J Viral Hepat"},{"key":"10365_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","volume":"19","author":"W Choi","year":"2021","unstructured":"Choi W, Choi J, Lim Y. Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:246\u2013258","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10365_CR31","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.3390\/cancers12113414","volume":"12","author":"H Lee","year":"2020","unstructured":"Lee H, Han D, Shin H, et al. Hepatocellular carcinoma risk according to regimens for eradication of hepatitis C virus; interferon or direct acting antivirals. Cancers (Basel). 2020;12:3414","journal-title":"Cancers (Basel)"},{"key":"10365_CR32","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/cncr.31291","volume":"124","author":"V Soriano","year":"2018","unstructured":"Soriano V, Tefferi A. Prevention of liver cancer with new curative hepatitis C antivirals: real-world challenges. Cancer. 2018;124:1647\u20131649","journal-title":"Cancer"},{"key":"10365_CR33","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","volume":"5","author":"H Sezaki","year":"2020","unstructured":"Sezaki H, Borghi J, Cheung R, Enomoto M, Nguyen M. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039\u20131052","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10365_CR34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","volume":"398","author":"P Gin\u00e8s","year":"2021","unstructured":"Gin\u00e8s P, Krag A, Abraldes J, Sol\u00e0 E, Fabrellas N, Kamath P. Liver cirrhosis. Lancet. 2021;398:1359\u20131376","journal-title":"Lancet"},{"key":"10365_CR35","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/j.1365-2893.2006.00778.x","volume":"13","author":"L Mart\u00edn-Carbonero","year":"2006","unstructured":"Mart\u00edn-Carbonero L, S\u00e1nchez-Somolinos M, Garc\u00eda-Samaniego J, N\u00fa\u00f1ez MJ, Gonz\u00e1lez-Lahoz J, Soriano V. Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. J Viral Hepat. 2006;13:851\u2013857","journal-title":"J Viral Hepat"},{"key":"10365_CR36","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1097\/QAD.0000000000000417","volume":"28","author":"V Soriano","year":"2014","unstructured":"Soriano V, Vispo E, Sierra-Enguita R, de Mendoza C, Fern\u00e1ndez-Montero JV, Labarga P. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. AIDS. 2014;28:2389\u20132394","journal-title":"AIDS"},{"key":"10365_CR37","unstructured":"Spanish Statistics Institute. Available online: http:\/\/www.ine.es\/en\/index.htm (Accessed on 15 Dec 2021)"},{"key":"10365_CR38","unstructured":"Grupo de trabajo del estudio de prevalencia de la infecci\u00f3n por hepatitis C en poblaci\u00f3n general en Espa\u00f1a; 2017\u20132018. Resultados del 2\u00ba Estudio de\u00a0Seroprevalencia\u00a0en Espa\u00f1a (2017\u20132018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019. https:\/\/www.mscbs.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/docs\/INFORME_INFECCION_VHC_ESPANA2019.pdf. Accessed Mar 2022"},{"key":"10365_CR39","first-page":"81","volume":"113","author":"J Crespo","year":"2021","unstructured":"Crespo J, Grupo t\u00e9cnico de cribado de la infecci\u00f3n por el VHC. Screening guide for hepatitis C virus infection in Spain. Rev Esp Enferm Dig. 2021;113:81\u201382","journal-title":"Rev Esp Enferm Dig"},{"key":"10365_CR40","first-page":"809","volume":"109","author":"J Turnes","year":"2017","unstructured":"Turnes J, Dom\u00ednguez-Hern\u00e1ndez M, Casado MA. Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. Rev Esp Enferm Dig. 2017;109:809\u2013817","journal-title":"Rev Esp Enferm Dig"},{"key":"10365_CR41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","volume":"4","author":"G Cooke","year":"2019","unstructured":"Cooke G, Andrieux-Meyer I, Applegate T, et al. Accelerating the elimination of viral hepatitis: a lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol. 2019;4:135\u2013184","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10365_CR42","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","volume":"17","author":"A Cox","year":"2020","unstructured":"Cox A, El-Sayed M, Kao J, et al. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020;17:533\u2013542","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10365_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev-virology-091919-062728","volume":"8","author":"T Block","year":"2021","unstructured":"Block T, Chang K, Guo J. Prospects for the global elimination of hepatitis B. Annu Rev Virol. 2021;8:437\u2013458","journal-title":"Annu Rev Virol"},{"key":"10365_CR44","first-page":"204993612096502","volume":"7","author":"V Soriano","year":"2020","unstructured":"Soriano V, Barreiro P, Cachay E, Kottilil S, Fernandez-Montero JV, de Mendoza C. Advances in hepatitis B therapeutics. Ther Adv Infect Dis. 2020;7:2049936120965027","journal-title":"Ther Adv Infect Dis"},{"key":"10365_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ijid.2021.10.052","volume":"114","author":"V Soriano","year":"2021","unstructured":"Soriano V, Alvarez C, Edagwa B, et al. Ultra-long acting (XLA) antivirals for chronic viral hepatitis. Int J Infect Dis. 2021;114:45\u201350","journal-title":"Int J Infect Dis"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10365-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-022-10365-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10365-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T03:30:24Z","timestamp":1664508624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-022-10365-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10365"],"URL":"https:\/\/doi.org\/10.1007\/s12072-022-10365-0","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jos\u00e9\u2011Manuel Ramos\u2011Rincon, H\u00e9ctor Pinargote\u2011Celorio, Carmen de Mendoza, Clara Ramos\u2011Belinch\u00f3n, Pablo Barreiro, Ana Trevi\u00f1o, Octavio Corral and Vicente Soriano acknowledged no conflicts of interest with this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Clinical Research Ethics Committee of the Alicante General University Hospital (Alicante, Spain) (ref. CEIm: PI2021-119). The procedures described here were carried out in accordance with the ethical standards described in the Revised Declaration of Helsinki in 2013.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}